Keyphrases
Aberrancy
9%
Aberrations
9%
CD10
9%
CD23
18%
CD5+
9%
Clinical Behavior
100%
Clinical Outcomes
100%
Clinical Presentation
18%
Clinical Response
9%
Co-expression
9%
Cyclin D1 (CCND1)
9%
Immunochemotherapy
9%
Immunophenotypic Profile
100%
Immunophenotyping
9%
Initial Treatment
18%
Laboratory Parameters
9%
Lymphocytosis
18%
Mantle Cell Lymphoma
100%
Mantle Cell Lymphoma International Prognostic Index
18%
Newly Diagnosed
9%
No Significant Difference
9%
Overall Survival
27%
Patient Selection
9%
Prognostic Score
27%
Progression-free Survival
27%
Response to Therapy
9%
Response to Treatment
9%
White Blood Cell Count
18%
Neuroscience
Behavior (Neuroscience)
100%
CD23
100%
CD5
50%
Cyclin D1
50%
Immunophenotyping
50%
Leukocyte
100%
Immunology and Microbiology
CD23
15%
CD5
7%
Cyclin D1
7%
Leukocyte Count
15%
Lymphoma Cell
100%
Overall Survival
23%
Progression Free Survival
23%
Pharmacology, Toxicology and Pharmaceutical Science
Cyclin D1
7%
Lymphocytosis
15%
Mantle Cell Lymphoma
100%
Overall Survival
23%
Progression Free Survival
23%